GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Suven Life Sciences Ltd

Suven Life Sciences Q1 FY27 Net Loss: Rs. (1,611.91) Lakhs Standalone

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 06 Aug 2026, 12:50 PM IST  ·  BSE ID: cf1d98c8-7908-431c-946f-bb4c33e10eb6
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its first quarter financial results, showing a net loss in both standalone and consolidated statements.
🤖 AI Summary
  • Board approved Un-Audited Standalone and Consolidated Financial Results for Q1 FY27 on August 6, 2026.
  • Standalone Net Loss for the quarter ended June 30, 2026, was Rs. (1,611.91) Lakhs.
  • Consolidated Net Loss for the quarter ended June 30, 2026, was Rs. (12,761.03) Lakhs.
  • Standalone Revenue from operations was Rs. 356.58 Lakhs; Consolidated Revenue was Rs. 356.58 Lakhs.
  • R&D Expenses stood at Rs. 1,275.60 Lakhs Standalone and Rs. 12,383.10 Lakhs Consolidated.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Revenue from operations Q1 FY27
356.58 Rs. In Lakhs
91.02
Standalone Net Profit/ (Loss) Q1 FY27
(1,611.91) Rs. In Lakhs
-9.07
Consolidated Revenue from operations Q1 FY27
356.58 Rs. In Lakhs
91.02
Consolidated Net Profit/ (Loss) Q1 FY27
(12,761.03) Rs. In Lakhs
-147.71
Standalone R&D Expenses Q1 FY27
1,275.60 Rs. In Lakhs
145.92
Consolidated R&D Expenses Q1 FY27
12,383.10 Rs. In Lakhs
198.59
🏢 How This Affects the Company
📈
Business Impact
The company operates solely in Research & Development, with significant R&D expenses incurred during the quarter.
💰
Financial Impact
The company reported net losses in both standalone and consolidated financials for the quarter, continuing a trend from the previous fiscal year. Finance costs increased to Rs. 47.61 Lakhs (Standalone and Consolidated) from Rs. 15.78 Lakhs in the prior quarter.
⚠️
Risk Impact
Continued significant net losses, combined with high R&D expenditures, indicate ongoing investment in development without immediate offsetting revenue streams. The company has a balance of Rs. 44,813.73 Lakhs from a preferential issue for future utilization.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the reported net losses, which impact earnings per share (Basic EPS Standalone: (0.61) and Consolidated: (4.84) for the quarter ended June 30, 2026).
🔍
Management Signal
The management's continued high R&D spending indicates a focus on long-term product development, despite current period losses.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q2 FY27 results — monitor net loss trend and R&D expenditure changes.
Updates on utilization of preferential issue proceeds of Rs. 44,813.73 Lakhs.
Allotment of pending 1,85,70,133 warrants and their conversion into equity shares.
HIGH RISK Substantial and increasing net losses in both standalone and consolidated financials, coupled with high R&D costs, present financial risk.
💡 Investor Takeaway
Suven Life Sciences reported a Standalone Net Loss of Rs. (1,611.91) Lakhs and a Consolidated Net Loss of Rs. (12,761.03) Lakhs for the quarter ended June 30, 2026. This represents a substantial increase in losses compared to the previous year, alongside significant R&D expenditure.
⚖️ Strengths & Concerns

✅ Positives

  • Significant Other Income of Rs. 752.36 Lakhs (Standalone and Consolidated) for the quarter ended June 30, 2026.
  • A balance amount of Rs. 44,813.73 Lakhs from a preferential issue is available for utilization as of June 30, 2026.

⚠️ Concerns

  • Standalone Net Loss increased to Rs. (1,611.91) Lakhs for Q1 FY27 from Rs. (1,477.87) Lakhs in Q1 FY26.
  • Consolidated Net Loss substantially increased to Rs. (12,761.03) Lakhs for Q1 FY27 from Rs. (5,151.69) Lakhs in Q1 FY26.
📅 Company Track Record
Suven Life Sciences had previously informed BSE on July 30, 2026, about the Board Meeting scheduled for August 6, 2026, to approve the Q1 FY27 un-audited financial results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Suven Life Sciences' standalone net profit/loss for Q1 FY27?
Suven Life Sciences reported a standalone Net Loss of Rs. (1,611.91) Lakhs for the quarter ended June 30, 2026, compared to a net loss of Rs. (1,477.87) Lakhs in the prior comparable period.
What was Suven Life Sciences' consolidated net profit/loss for Q1 FY27?
The consolidated Net Loss for Suven Life Sciences for the quarter ended June 30, 2026, was Rs. (12,761.03) Lakhs, significantly higher than the Rs. (5,151.69) Lakhs net loss in Q1 FY26.
What were the R&D Expenses for Suven Life Sciences in Q1 FY27?
Standalone R&D Expenses were Rs. 1,275.60 Lakhs, and Consolidated R&D Expenses were Rs. 12,383.10 Lakhs for the quarter ended June 30, 2026.
How much fund from preferential issue is unutilized by Suven Life Sciences?
As of June 30, 2026, Suven Life Sciences has a balance unutilized amount of Rs. 44,813.73 Lakhs from its preferential issue.
What was Suven Life Sciences' Revenue from operations for Q1 FY27?
Both Standalone and Consolidated Revenue from operations for Suven Life Sciences were Rs. 356.58 Lakhs for the quarter ended June 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.